-
Selective review and commentary on emerging pharmacotherapies for opioid addiction.
Ling W, Mooney L, Zhao M, Nielsen S, Torrington M, Miotto K. Selective review and commentary on emerging pharmacotherapies for opioid addiction. Substance Abuse and Rehabilitation 2011;2(1):181-188.
-
The Appalachian Tri-State Node experiences with the National Institute on Drug Abuse Clinical Trials Network.
Kelly TM, Daley DC, Byrne M, DeMarco L, Smith D, Madl S. The Appalachian Tri-State Node experiences with the National Institute on Drug Abuse Clinical Trials Network. Mind & Brain 2011;2(1):56-66.
-
Depressive symptoms, substance use and HIV-related high risk behaviors among opioid-dependent individuals: Results from the Clinical Trials Network.
Pilowsky DJ, Wu L, Burchett B, Blazer DG, Ling W. Depressive symptoms, substance use and HIV-related high risk behaviors among opioid-dependent individuals: Results from the Clinical Trials Network. Substance Use and Misuse 2011;46(14):1716-1725.
-
Stimulant Reduction Intervention Using Dosed Exercise (STRIDE) – CTN 0037: Study protocol for a randomized controlled trial.
Trivedi MH, Greer TL, Grannemann BD, Church TS, Somoza EC, Blair SN, Szapocznik J, Stoutenberg M, Rethorst C, Warden D, Ring KM, Walker NR, Morris DW, Kosinski AS, Kyle T, Marcus B, Crowell B, Oden N, Nunes EV. Stimulant Reduction Intervention Using Dosed Exercise (STRIDE) - CTN 0037: Study protocol for a randomized controlled trial. Trials 2011;12:206.
-
Determining the primary endpoint for a stimulant abuse trial: Lessons learned from STRIDE (CTN 0037).
Trivedi MH, Greer TL, Potter JS, Grannemann BD, Nunes EV, Rethorst C, Warden D, Ring KM, Somoza EC. Determining the primary endpoint for a stimulant abuse trial: Lessons learned from STRIDE (CTN 0037). American Journal of Drug and Alcohol Abuse 2011;37(5):339-349.
-
NIDA’s Clinical Trials Network: An opportunity for HIV research in community substance abuse treatment programs.
Tross S, Campbell ANC, Calsyn DA, Metsch LR, Sorensen JL, Shoptaw S, Haynes LF, Woody GE, Malow RM, Brown LS Jr, Feaster DJ, Booth RE, Mandler RN, Masson CL, Holmes BW, Colfax GN, Brooks AJ, Hien DA, Schackman BR, Korthuis PT, Miele GM. NIDA’s Clinical Trials Network: An opportunity for HIV research in community substance abuse treatment programs. American Journal of Drug and Alcohol Abuse 2011;37(5):283-293.
-
Relation of study design to recruitment and retention in CTN trials.
Wakim PG, Rosa CL, Kothari P, Michel ME. Relation of study design to recruitment and retention in CTN trials. American Journal of Drug and Alcohol Abuse 2011;37(5):426-433.
-
Assessing drug use during follow-up: Direct comparison of candidate outcome definitions in pooled analyses of addiction treatment studies.
Korte JE, Magruder KM, Chiuzan CC, Logan SL, Killeen T, Bandyopadhyay D, Brady KT. Assessing drug use during follow-up: Direct comparison of candidate outcome definitions in pooled analyses of addiction treatment studies. American Journal of Drug and Alcohol Abuse 2011;37(5):358-366.
-
Baseline matters: The importance of covariation for baseline severity in the analysis of clinical trials.
Nunes EV, Pavlicova M, Hu M, Campbell ANC, Miele GM, Hien DA, Klein DF. Baseline matters: The importance of covariation for baseline severity in the analysis of clinical trials. American Journal of Drug and Alcohol Abuse 2011;37(5):446-452.
-
Strategies for safety reporting in substance abuse trials.
Lindblad R, Campanella M, Styers D, Kothari P, Sparenborg S, Rosa CL. Strategies for safety reporting in substance abuse trials. American Journal of Drug and Alcohol Abuse 2011;37(5):440-445.